Cite
MLA Citation
Norbert Vey et al.. “Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia.” Leukemia & lymphoma, vol. 58, no. 8, 2017, pp. 1880–1886. http://access.bl.uk/ark:/81055/vdc_100044447686.0x000017